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algorithms mapping FACT-G to EuroQol (EQ-5D) [(Cheung, 2009), Ordinary Least 
Squares (OLS) and Tobit (Longworth, 2014)] and one from FACT-G to Time-Trade-
Off (Dobrez, 2007) were applied to data from the phase II study. The agreement 
between HSUVs was assessed using concordance correlation coefficients (CCCs), 
and paired t-tests for mean HSUVs. Results: HSUVs were generated for 93% of 
patients in the study. Mean predicted HSUVs using OLS and Tobit were statisti-
cally consistent (p-value= 0.947), whilst Cheung and Dobrez HSUVs were different 
from other algorithms (p-values < 0.05). The CCCs comparing OLS to Tobit and 
OLS to Cheung were 0.915 and 0.851, respectively. The CCCs comparing Dobrez 
to the EQ-5D algorithms were 0.629 (OLS), 0.619 (Tobit) and 0.783 (Cheung). The 
lowest and highest mean predicted HSUVs were estimated using OLS and Dobrez, 
respectively. ConClusions: HSUVs can be estimated from FACT-O using FACT-G 
mapping algorithms. Comparable HSUVs were generated using OLS and Tobit algo-
rithms, whilst Cheung and Dobrez generated distinct HSUVs profiles. Without trial 
data directly comparing EQ-5D to FACT-O, it is difficult to identify the optimal 
mapping algorithm. Instead, a range of plausible mean HSUVs can be derived for 
use in cost-utility analyses.
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objeCtives: To compare indirect utilities for prostate cancer patients obtained 
with a generic (SF-6D) and a disease-specific instrument (Patient Oriented Prostate 
Utility Scale, PORPUS-U). Methods: This was a cross-sectional study of 480 pros-
tate cancer patients enrolled in two similar prospective cohorts. The first one 
included men diagnosed in 2003-2005 with localized prostate cancer (stage T1 
or T2) treated with radical prostatectomy, external radiotherapy, or interstitial 
radiotherapy at 10 hospitals. The second cohort included patients with stage T2 
or T3, treated with external radiotherapy alone or combined with brachytherapy, 
recruited in 2003–2006 at 6 hospitals. Annual computer-assisted telephone inter-
views carried out in both cohorts included several questionnaires: the SF-36v2 
(from which is derived the SF-6D), the PORPUS-U, and the Expanded Prostate 
Cancer Index Composite (EPIC), measuring urinary, bowel, sexual, and hormonal 
domains. ANOVA tests were performed to compare the means of utilities among 
severity groups of severity defined by EPIC items (severe, small or no relevant 
problem). Effect sizes between extreme groups were calculated to estimate the 
magnitude of differences. Results: Mean age was 66.8 years (SD= 6.4) at pros-
tate cancer diagnosis, 20.4% were treated with radical prostatectomy, 33.3% with 
brachytherapy, 26.7% with external radiotherapy, and 19.6% with combined radio-
therapy. The utilities indirectly obtained ranged 0.83-0.99 with PORPUS-U and 
0.61-0.84 with SF-6D. Both instruments showed significant differences according 
to problem severity of all domains measured with EPIC (p< 0.001). Utilities for 
patients without problems were higher than patients with severe problems. The 
effect sizes between the extreme groups with PORPUS-U and SF-6D were: 1.23 and 
1.24 for urinary; 1.03 and 0.75 for bowel; 0.98 and 0.96 for sexual; and 0.94 and 2.17 
for hormonal domains. ConClusions: Our results suggest that both the generic 
index SF-6D and the disease-specific index PORPUS-U discriminated adequately 
the problems related to prostate cancer and their treatments.
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objeCtives: The primary objective of this French prospective multicenter non 
interventional ODISSEE study was to describe daily practice management of 
infra-centimetric Breast Cancer (BC). One secondary objective was to describe 
circumstances of diagnosis and disease announcement. Patients had to answer 
at inclusion a questionnaire regarding satisfaction of the management of their 
disease and upcoming treatment. Methods: From May 2009 to March 2010, 616 
women with infiltrating, unifocal pT1ab, pN0 BC who underwent surgery were 
recruited by 116 centers. Follow-up period is 10 years. Clinical data, treatments 
and outcome were collected in routine visits. Regarding patient’s questionnaire 
at inclusion, seven topics (disease, treatment planned/organization/duration/
side effects, complementary exams needed and disease evolution) were to be 
discussed with their physician at disease discovery and patient’s satisfaction was 
evaluated. Results: 546 (89%) patients answered the questionnaire. All 7 topics 
were discussed with 52% of patients and none of them for 1% of patients. Disease 
and treatment planned was discussed for 98% of patients, for whom 67% were 
fully satisfied and 2% were not satisfied. While 60% of patients aged more than 
50 years old felt fully involved in their treatment choice, only 44% of patients 
aged less than 50 years old felt involved. Overall 12% of patients have considered 
that they have not been involved in their treatment choice. When time between 
disease discovery/physician visit/surgery is short (< 10 days), patient satisfac-
tion is high (> 85%) and when time is greater than 1 month, patient satisfaction 
falls below 40%. Physican specialty (surgeon/oncologist/gyneco-obstetrician) or 
location of disease management (public/private) does not show significant dif-
ference in patient’s satisfaction. ConClusions: 57% of patients felt involved in 
the choice of their treatment, and 65% of patients were globally satisfied of their 
disease management. The shorter is the management of infra-centimetric breast 
cancer, the better is the satisfaction.
values ranged from 0.81–0.90. Pain, severity of disease, urinary and bowel function 
and performance status affected utility values in patients with PC. ConClusions: 
For BC and PC, disease progression, exposure to CT and worsening performance 
status were associated with decreases in utility values. For corresponding disease 
stages, utility values tended to be lower for BC than PC, although heterogeneity of 
data across study populations makes comparisons challenging. No studies reported 
utility values according to response to treatment. Further research is warranted to 
improve the evidence available for CEA.
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objeCtives: The study is designed to capture health related quality of life (HRQL) 
weights for radioiodine refractory differentiated thyroid cancer (RR-DTC) health 
states. Current treatment options for RR-DTC are limited, with generally poor prog-
nosis. As new treatments emerge for RR-DTC, associated cost-effectiveness evalu-
ations require appropriate preference-weighted HRQL values. Methods: Vignette 
descriptions for RR-DTC treatment response and adverse event (AE) health states 
were informed by qualitative work conducted with RR-DTC patients in the US and 
interviews with 6 clinicians and nurses in the UK and US with RR-DTC treatment 
experience. Health states included: stable disease, treatment response, progressive 
disease, stable + grade III diarrhea, stable + grade III fatigue, stable + grade III hand 
foot syndrome (HFS), stable + grade I-II alopecia. The vignettes were reviewed by 
the UK and US clinical experts and piloted with UK general public participants 
in cognitive debrief interviews (n= 5). All vignettes were valued by a UK general 
public sample (n= 100) using a visual analogue scale (VAS) rating and time trade 
off (TTO) interview. Data were analysed using descriptive and regression meth-
ods. Results: The mean TTO health utilities for RR-DTC states ranged from treat-
ment response (0.86; 95% confidence intervals (CI) 0.83,0. 89); through stable disease 
(0.80; CI 0.77, 0.84); to progressive disease (0.50; CI 0.45, 0.56). AEs had a significant 
effect also (stable + grade I-II alopecia (0.75; CI 0.71, 0.79), + grade III fatigue (0.72; 
CI 0.67, 0.77), + grade III HFS (0.52; CI 0.46, 0.58), and + grade III diarrhea (0.42; CI 
0.36-0.48). ConClusions: TTO utilities from this vignette study show clear dif-
ferentiation between RR-DTC states. The order and magnitude of HRQL impact 
demonstrated by the utility values reflected clinical opinion and elicited VAS scores. 
The values reported in this study are suitable for use in cost-effectiveness evalua-
tions for new treatments in RR-DTC.
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objeCtives: Since October 2013, the Haute Autorité de Santé (HAS) requires cost-
effectiveness evidence to assess innovative health technologies. For cost-utility 
assessments, the HAS strongly recommends using French utility values. To date, 
the EQ-5D-3L and the HUI3 are the only instruments with a set of preferences 
values obtained from a representative sample of the French population. In order 
to inform a cost-utility model assessing pharmaceutical treatments of previously-
treated iNHL, this study aimed to review available utility values in France and 
to collect such estimates if necessary. Methods: First, a reproducible MEDLINE 
search was undertaken to identify studies documenting utility values of previously 
treated iNHL and CLL in France. Then, a web-survey including socio-demographic 
and clinical questions as well as the EQ-5D-3L was conducted. Given the difficulty 
to recruit patients from the target population, the questionnaire was conducted 
in France, the United Kingdom, Germany, Italy and Spain. In line with the HAS 
guidelines, French tariffs from Chevalier et al. were applied to the collected EQ-5D 
data. Mean utility values were generated by health state: progression free and 
progressive disease. Results: Only one French cost-utility model conducted by 
Deconinck E. et al was identified as relevant, but the study used English utility 
inputs previously published by Wild et al. Results from the EQ-5D-3L questionnaire 
conducted, illustrated that quality of life was substantially higher in patients with 
stable disease versus patients with progression disease. Utilities were calculated 
with the following scoring function, U (E) = 1–u1-u2-u3-u4-u5–N3. Values between 
u1 to u5 depending of the 3 levels of the 5 dimensions: u1= 0; 0.15; 0.37, u2= 0; 0.21;. 
32; u3= 0; 0.16; 0.19; u4= 0; 0.11;. 026; u5= 0; 0.09; 0.20 and N3= 0.17. ConClusions: 
EQ-5D is a standardised and validated generic instrument which can be used to 
elicit utility in iNHL patients. To our knowledge, these French utilities of previ-
ously-treated iNHL patients are the first to be published.
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objeCtives: Where direct or indirect estimates of health state utility values 
(HSUVs) are not available, mapping algorithms can be used to generate HSUVs 
from health related quality of life data. In a phase II randomised study of olapa-
rib maintenance therapy in platinum-sensitive recurrent ovarian cancer, the 
Functional Assessment of Cancer Therapy Ovarian (FACT-O) questionnaire was 
used. Although no FACT-O mapping algorithms are currently available, several 
algorithms using FACT-General (G) domains of FACT-O have been published. In 
this analysis, we applied FACT-G mapping algorithms to the FACT-O data collected 
in the olaparib study and compared the HSUVs generated. Methods: FACT-O 
data were collected at scheduled visits, and on treatment discontinuation. Three 
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month after of the surgery we applied EORTC questionnaires QLQ-C30, PR25, and 
IN-PATSAT32. The scores for each questionnaire were calculated according formulas 
and instruction in the EORTC Scoring Manual. We calculated mean and standard 
deviation for each score. Results: Global Health Status/QoL has a mean score 74.80 
(±20.74); the functional scales: physical 87.4 (±18.08); emotional 80.3 (±17.23); role 
87.6 (±24.44), social 89.4 (±20.09). Symptoms scales: fatigue 15.6 (±15.48); insomnia, 
27.3 (±30.00), pain 12 (±17.27), constipation 18.4 (±27.63), financial difficulties 17 
(±29.38) the others symptom scales showed mean scores under 10. For scales in PR25 
questionnaire, the scores were: sexual activity 72.7 (±20.68), sexual function 59.0 
(±31.45); urinary symptoms 32.5 (±21.57), symptoms related with hormonal therapy 
17.5 (±14.13), incontinence support 29.2 (±38.24). About scores for IN-PATSAT32, for 
doctors: Interpersonal skills 88.30 (±16.72); technical skills 87.23 (±19.95); capacity 
to bring information 89.01 (±17.29); availability 88.56 (±16.85); for nurse: interper-
sonal skills 87.41 (±16.74) technical skills 86.52 (±18.51); capacity to bring infor-
mation 84.40 (±19.00); availability 79.26 (±20.89); other personnel kindness 80.85 
(±20.47), access 76.86 (±23.16), waiting time 82.18 (±21.45), exchange of informa-
tion 77.66 (±22.86), comfort/cleanness 80.85 (±21.62) and general satisfaction 84.57 
(±18.46). ConClusions: The functional scales for QLQ-C30 showed a good quality 
of life, however symptom scales related to sexual function showed a diminished 
QoL, satisfaction with doctors and nurses is good, but not for other personnel.
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objeCtives: To determine the HRQoL scores in multiple myeloma patients who 
are receiving treatment in a tertiary referral hospital. Methods: Outpatients 
attended consecutively at the hematology department were enrolled, at any 
stage of treatment. We interviewed through EORTC questionnaires: QLQ30, MY20 
and INPATSAT32. The medians and percentiles were calculated. Questionnaire 
scores were calculated according to formulas and instructions of the EORTC scor-
ing manual. Results: 23 patients were analyzed; the median of age was 62.21 
years (interquartile interval 59.02-69.88). 69.56% were men. Global health status/
QoL showed a median score of 66.67 (P25= 62.5, P75= 83.33), emotional function-
ing 83.33 (P25= 58.33, P75= 91.66), pain scale 33.33 (P25= 16.66, P75= 50.00), insom-
nia 33.33 (P25= 0, P75= 33.33), fatigue 33.33 (P25= 16.66, P75= 44.44). The median for 
the body image scale was 100.00 (P25= 50.00, P75= 100.00) and future perspective 
was 77.78 (P25= 55.55, P75= 97.22), the other medians: symptoms 27.78 (P25= 13.88, 
P75= 38.88), treatment-related side effects 20.00 (P25= 8.33, P75= 36.66). In the sat-
isfaction questionnaire, the scores for the doctor showed: technical skills 75.00 
(P25= 54.16, P75= 97.91), information provided 41.67 (P25= 25.00, P75= 58.33) for nurs-
ing: technical skills 75.00 (P25= 58.33, P75= 89.58) and information provided 75.00 
(P25= 50.00, P75= 91.66), waiting times 62.50 (P25= 50.00, P75= 96.87) and in overall 
satisfaction average was 75.00 (P25= 50.00, P75= 93.75). ConClusions: Multiple 
myeloma patients treated in this hospital show favorable results on scores of qual-
ity of life in terms of symptoms of the disease and treatment-related side effects, 
especially in the fatigue. These results can be compared satisfactory accordingly 
with other reports from the international literature.
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objeCtives: To determine HRQoL and patient satisfaction scores in colorectal can-
cer patients treated through radical surgery with a curative intent. Methods: Were 
selected colorectal cancer patients treated through radical surgery. One month after 
of the surgery we applied EORTC questionnaires QLQ-C30, CR29, and IN-PATSAT32. 
The scores for each questionnaire were calculated according formulas and instruc-
tion in the EORTC Scoring Manual. We calculated median and percentilar values 
25 and 75 for each score. Results: Were studies 83 colorectal cancer patients: 
34 women and 49 men, the results for EORTC questionnaires are: Global Health 
Status/QoL has a median score 83.33 (70.83-100); the functional scales: physical 93.33 
(83.33-100); emotional 83.33 (75-91.67); role 100 (83.33-100), social 100 (83.33-100). 
Symptoms scales: fatigue 11.11 (0.00-33.33); insomnia, 0.00 (0.00-0.00), pain 0.00 
(0.00-16.67), constipation 0.00 (0.00-33.33), financial difficulties 0.00 (0.00-33.33). For 
scales in CR29 questionnaire, the scores were: body image 100 (83.3-100), anxiety 
66.67 (66.67-100); sexual interest in women 0.00 (0.00-33.33), sexual interest male 
33.33 (0.00-33.33), urinary frequency 16.67 (0.00-33.33), blood stool 0.00 (0.00-16.67), 
stool frequency 0.00 (0.00-16.66), urinary incontinence 0.00 (0.00-0.00). About scores 
for IN-PATSAT32, for doctors: Interpersonal skills 100 (91.66-100); technical skills 
100 (95.83-100); capacity to bring information 100 (91.66-100); availability 100 (100-
100); for nurse: interpersonal skills 100 (91.66-100) technical skills 100 (83.33-100); 
capacity to bring information 91.67 (70.83-100); availability 87.50 (75.00-100); other 
personnel kindness 91.67 (83.33-100), access 87.50 (62.5-100), waiting time 87.50 
(62.5-100), exchange of information 100 (75-100), comfort/cleanness 75.00 (75.00-100) 
and general satisfaction 75.00 (75.00-100). ConClusions: The functional scales for 
QLQ-C30 showed a good quality of life, however symptom scales related to sexual 
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objeCtives: To explore individual’s preferences concerning genetic screening for 
colorectal cancer (CRC) within a population-based CRC screening program and to 
calculate the initial uptake of genetic screening for different scenarios based on 
the three major categories of genetic CRC; familial adenomatous polyposis (FAP), 
hereditary non-polyposis colorectal cancer or Lynch syndrome and other famil-
ial non-polyposis colorectal cancer (FCC). Methods: By means of ongoing data 
collection, a Discrete Choice Experiment (DCE) questionnaire was sent to a rep-
resentative sample of the Dutch population aged 55-65years. The DCE included 
nine D-efficient designed choice tasks. Panel-mixed-logit models were used to 
estimate the relative importance of the four included genetic screening attrib-
utes; risk of being genetically predisposed, risk of developing CRC, frequency of 
follow-up colonoscopies, survival rate. The potential uptake was calculated for the 
three screening scenarios. Results: When the chance of being genetically predis-
posed increased, respondents were more likely to participate in genetic screening. 
Respondents preferred biannual and annual colonoscopies over having a follow-up 
colonoscopy every 5 years. Increasing predicted CRC survival rates were associ-
ated with increased willingness to participate in screening. The risk of developing 
CRC as a result of being genetically predisposed did not impact the willingness of 
respondents to participate in screening. The frequency of follow-up colonoscopies 
was relatively most important for respondents when deciding about participation 
in genetic screening. The calculated potential uptake rates were high with respec-
tively 91.3% for the FCC, 91.9% for the Lynch and 91.0% for the FAP screening sce-
nario. ConClusions: Individuals are willing to participate in genetic screening for 
CRC. This decision is mostly driven by the frequency of follow-up colonoscopies, CRC 
survival rate and the chance of being genetically predisposed. This interest of the 
general public in genetic screening should be taken into account when discussing 
about the possibility of introducing genetic screening in population-based cancer 
screening programs.
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objeCtives: MBC is an incurable disease for which NVBOral is a standard treat-
ment available in 45 countries. The burden of disease, treatment patterns and 
motivation to choose across treatments and their consequences are seldom 
described in the real world. Methods: A prospective observational study was 
conducted to assess the global burden of disease and treatment with NVBOral or 
ivVino in Czech Republic, France, Germany, Italy, Poland and Spain. Patients and 
disease characteristics at inclusion, events, tolerability, hospitalisations observed 
during one cycle of treatment, and reasons to choose either route of administra-
tion are described. Eligible patients received NVBOral either alone or combined 
with capecitabine, or ivVino either alone or combined with capecitabine or tras-
tuzumab. Results: 184 patients were registered in 6 European countries: 128 
with NVBOral and 56 with ivVino. Patients’ characteristics differed significantly 
only in term of age (64 years for NVBOral and 58 years for ivVino, p= .001) and 
time between diagnosis and inclusion (104 and 71 months respectively, p= .002). 
NVBOral was mainly given to patients with HER2-negative (90%), estrogen-pos-
itive (80%) and progesterone-positive (62%) disease (ivVino: 66%, 66% and 51% 
respectively). Patients in the two cohorts had similar performance status and 
were similarly distributed across chemotherapy lines. NVBOral was mainly chosen 
for patients’ convenience (93%) and upon patients’ request (21%) (ivVino: 30% 
and 12% respectively). The two treatments were similarly safe, with grade 3/4 
neutropenia in 2% with NVBOral and 6% with ivVino, nausea and vomiting in 2% 
and none respectively. NVBOral was given without interruption, delay, or dose 
adjustment in 85% of patients (ivVino: 78%). Hospitalisation was required during 
the cycle observed for 14% and 26% of patients respectively. ConClusions: In 
this European prospective observational study, NVBOral appeared a safe, patient-
convenient and easy to manage treatment for MBC patients. NVBOral is used 
particularly after hormonal therapy.
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objeCtives: To determine HRQoL and patient satisfaction scores in prostate cancer 
patients treated through radical prostatectomy with a curative intent. Methods: 
Were selected prostate cancer patients treated through radical prostatectomy. One 
